Anticoagulation Monitoring
Authors:
- 1 October 2004
- journal article
- research article
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 17 (5) , 317-326
Abstract
Optimal management of anticoagulant therapy requires an understanding of the laboratory tests often employed to guide therapy. The activated partial thromboplastin time (aPTT) can detect abnormalities in the intrinsic and common clotting pathways. Despite numerous limitations in the aPTT test, it remains the gold standard for monitoring unfractionated heparin and direct thrombin inhibitor therapy. The aPTT can be performed in the central laboratory or at the bedside (point of care [POC] testing). The activated clotting time (ACT) is a POC test that is routinely employed to monitor high-dose heparin during invasive and surgical procedures. The ACT therapeutic range will depend on the specific procedure or surgery being performed. Heparin levels are becoming more routinely available and are used to establish the aPTT therapeutic range for heparin therapy as well as for direct monitoring of heparin and low-molecular-weight heparin therapy. The international normalized ratio (INR) is the gold standard for monitoring warfarin patients. The target INR depends on the indication for anticoagulation. POC monitoring for warfarin is becoming increasingly used. Clinicians should have a thorough understanding of the benefits as well as the limitations of warfarin POC monitoring.Keywords
This publication has 74 references indexed in Scilit:
- Implementing a New Method for Activated Clotting Time:Point of Care: The Journal of Near-Patient Testing & Technology, 2003
- Monitoring of Anticoagulant Effects of Direct Thrombin InhibitorsSeminars in Thrombosis and Hemostasis, 2002
- An Investigation of a New Activated Clotting Time “MAX-ACT” in Patients Undergoing Extracorporeal CirculationAnesthesia & Analgesia, 2001
- Use of the Activated Partial Thromboplastin Time for Heparin MonitoringAmerican Journal of Clinical Pathology, 2001
- Effect of heparin on whole blood activated partial thromboplastin time using a portable, whole blood coagulation monitorCritical Care Medicine, 1995
- Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)The American Journal of Cardiology, 1995
- On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromesThe American Journal of Cardiology, 1993
- Adequate heparinization during PTCA: Assessment using activated clotting timesCatheterization and Cardiovascular Diagnosis, 1989
- Comparison of High-Dose with Low-Dose Subcutaneous Heparin to Prevent Left Ventricular Mural Thrombosis in Patients with Acute Transmural Anterior Myocardial InfarctionNew England Journal of Medicine, 1989
- Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1986